Mesenchymal stem cell-derived extracellular vesicle-based therapies protect against coupled degeneration of the central nervous and vascular systems in stroke

Rahmani, Abolfazl; Saleki, Kiarash; Javanmehr, Nima; Khodaparast, Javad; Saadat, Payam; Nouri, Hamid Reza

doi:10.1016/j.arr.2020.101106

Cited by 76 publications

(70 citation statements)

References 272 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SARS-CoV, MERS-CoV, and SARS-CoV2 are human CoVs (hCoVs) that have been the cause of three outbreaks during the last two decades ( Jabbari et al, 2020 ). All of them have shown the potential to manifest as multisystem difficult to treat infections ( Goudarzi et al, 2020 ; Heidarpour et al, 2020 ; Jahanshahlu and Rezaei, 2020a ; Jenab et al, 2020 ; Nejadghaderi et al, 2020 ; Rahmani et al, 2020 ; Sadeghmousavi and Rezaei, 2020 ; Yazdanpanah et al, 2020b ). In particular, multisystem involvement in COVID-19 has been associated with anti-viral immunity paralysis on the one hand, and on the other hand release of pro-inflammatory cytokines, e.g., interleukin-6, and hyperinflammatory shock ( Bahrami et al, 2020 ; Fathi and Rezaei, 2020 ; Mojtabavi et al, 2020 ; Nasab et al, 2020 ; Rokni et al, 2020 ; Saghazadeh and Rezaei, 2020a ; Sarzaeim and Rezaei, 2020 ; Yazdanpanah et al, 2020a ).…”

Section: Discussionmentioning

confidence: 99%

Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies

Saleki

Yaribash

Banazadeh

et al. 2021

European Journal of Pharmacology

Self Cite

View full text Add to dashboard Cite

Concern regarding coronavirus (CoV) outbreaks has stayed relevant to global health in the last decades. Emerging COVID-19 infection, caused by the novel SARS-CoV2, is now a pandemic, bringing a substantial burden to human health. Interferon (IFN), combined with other antivirals and various treatments, has been used to treat and prevent MERS-CoV, SARS-CoV, and SARS-CoV2 infections. We aimed to assess the clinical efficacy of IFN-based treatments and combinational therapy with antivirals, corticosteroids, traditional medicine, and other treatments. Major healthcare databases and grey literature were investigated. A three-stage screening was utilized, and included studies were checked against the protocol eligibility criteria. Risk of bias assessment and data extraction were performed, followed by narrative data synthesis. Fifty-five distinct studies of SARS-CoV2, MERS-CoV, and SARS-CoV were spotted. Our narrative synthesis showed a possible benefit in the use of IFN. A good quality cohort showed lower CRP levels in Arbidol (ARB) + IFN group vs. IFN only group. Another study reported a significantly shorter chest X-ray (CXR) resolution in IFN-Alfacon-1 + corticosteroid group compared with the corticosteroid only group in SARS-CoV patients. In a COVID-19 trial, total adverse drug events (ADEs) were much lower in the Favipiravir (FPV) + IFN-α group compared with the LPV/RTV arm (P = 0.001). Also, nausea in patients receiving FPV + IFN-α regimen was significantly lower (P = 0.03). Quantitative analysis of mortality did not show a conclusive effect for IFN/RBV treatment in six moderately heterogeneous MERS-CoV studies (log OR=-0.05, 95% CI: (-0.71,0.62), I 2 =44.71%). A meta-analysis of three COVID-19 studies did not show a conclusive nor meaningful relation between receiving IFN and COVID-19 severity (log OR=-0.44, 95% CI: (-1.13,0.25), I 2 =31.42%). A lack of high-quality cohorts and controlled trials was observed. Evidence suggests the potential efficacy of several combination IFN therapies such as lower ADEs, quicker resolution of CXR, or a decrease in inflammatory cytokines; Still, these options must possibly be further explored before being recommended in public guidelines. For all major CoVs, our results may indicate a lack of a definitive effect of IFN treatment on mortality. We recommend such therapeutics be administered with extreme caution until further investigation uncovers high-quality evidence in favor of IFN or combination therapy with IFN.

show abstract

Section: Discussionmentioning

confidence: 99%

Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies

Saleki

Yaribash

Banazadeh

et al. 2021

European Journal of Pharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Stem cell-derived extracellular vesicles (EVs) are favored as an alternative to cell transplantation [ 133 , 134 ]. EVs, including RNA, protein, and lipid metabolites, are able to circulate in the blood and cross the blood-brain barrier [ 135 , 136 ].…”

Section: Discussionmentioning

confidence: 99%

Characteristics, Classification, and Application of Stem Cells Derived from Human Teeth

Tong

Zhang

2021

Stem Cells International

View full text Add to dashboard Cite

Since mesenchymal stem cells derived from human teeth are characterized as having the properties of excellent proliferation, multilineage differentiation, and immune regulation. Dental stem cells exhibit fibroblast-like microscopic appearance and express mesenchymal markers, embryonic markers, and vascular markers but do not express hematopoietic markers. Dental stem cells are a mixed population with different sensitive markers, characteristics, and therapeutic effects. Single or combined surface markers are not only helpful for understanding the subpopulation of mixed stem cell populations according to cell function but also for improving the stable treatment effect of dental stem cells. Focusing on the discovery and characterization of stem cells isolated from human teeth over the past 20 years, this review outlines the effect of marker sorting on cell proliferation and differentiation ability and the assessment of the clinical application potential. Classified dental stem cells from markers and functional molecules can solve the problem of heterogeneity and ensure the efficacy of cell therapy strategies including dentistry, neurologic diseases, bone repair, and tissue engineering.

show abstract

“…It is worth mentioning that some researchers have proposed to use Exos from MSCs as a medium for OS treatment in light of the stem characteristics of MSCs. It has been revealed currently that MSCs can restrict inflammation, reprogram immune cells, and activate endogenous repair pathways (Rahmani et al, 2020;Ullah et al, 2020;, and…”

Section: Conclusion and Prospectsmentioning

confidence: 99%

The potential roles of exosomal noncoding RNAs in osteosarcoma

Wang

2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Clinically, it is difficult to efficaciously screen and diagnose osteosarcoma (OS) in advance due to the low sensitivity and poor specificity of the existing tumor markers. Exosomes (Exos) are nanoscale vesicles containing RNAs, lipids, and proteins with a diameter of 30–100 nm. They are multivesicular bodies formed during the invagination of lysosomal particles in cells and released extracellularly after fusing with cell membranes. Besides, Exos are important carriers of cell‐to‐cell communication signals and genetic materials in the tumor microenvironment. During tumorigenesis, the tumor cells interplay with immune cells, endothelial cells, and related fibroblasts through Exos and boost cancer development. After altering the surrounding microenvironment, the Exos drive tumor cells to proliferate, speed up angiogenesis, and boost cancers to develop along with body fluid transportation. Currently, Exos are becoming novel noninvasive tumor diagnostic markers with high sensitivity, exerting pivotal impacts in fundamental research and clinical applications. Here, we review the existing literature on the roles of exosomal noncoding RNAs in OS progression and their potential clinical applications as novel biomarkers and therapeutics.

show abstract

Mesenchymal stem cell-derived extracellular vesicle-based therapies protect against coupled degeneration of the central nervous and vascular systems in stroke

Cited by 76 publications

References 272 publications

Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies

Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies

Characteristics, Classification, and Application of Stem Cells Derived from Human Teeth

The potential roles of exosomal noncoding RNAs in osteosarcoma

Contact Info

Product

Resources

About